CARB-X IS FUNDING SWISS PHARMA COMPANY BIOVERSYS TO DEVELOP A NEW CLASS OF ANTIBIOTICS TO TREAT INFECTIONS CAUSED BY MULTIDRUG-RESISTANT ESKAPE PATHOGENS

  02 June 2021

The award from CARB-X (the Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator) will help BioVersys develop BV300, a novel class of small molecules called pyrrolocytosines that target the ribosome, which is an unexploited binding site in bacterial pathogens. The molecules have demonstrated coverage of both gram-negative and gram-positive bacteria in preclinical testing, including the ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species).

CARB-X is awarding BioVersys, a pharmaceutical company headquartered in Basel, Switzerland, up to US$4.35 million in non-dilutive funding, to develop a new class of antibiotics to treat life-threatening infections caused by ESKAPE pathogens, bacteria that have developed resistance to most antibiotics available today. BioVersys could receive up to $10.98 million in additional funds from CARB-X if the project achieves certain milestones, subject to available funds.

Further reading: CARB-X
Author(s): Jennifer Robinson
Smart Innovations  
Back

OUR UNDERWRITERS

Unrestricted financial support by:

Antimicrobial Resistance Fighter Coalition

Bangalore Bioinnovation Centre

INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS

BD





AMR NEWS

Every two weeks in your inbox

Because there should be one newsletter that brings together all One Health news related to antimicrobial resistance: AMR NEWS!

Subscribe

What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!

Keep me informed